Key Takeaways:
- FDA accepts Praxis' new drug application for ulixacaltamide in adults.
- The agency set a PDUFA target action date of January 29, 2027.
- The acceptance is a significant de-risking event for the company.
Back
Back
Praxis Precision gets January 29 FDA review date for tremor drug
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced its New Drug Application (NDA) for ulixacaltamide HCl for the treatment of essential tremor in adults has been accepted for review by the U.S. Food and Drug Administration (FDA).
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of January 29, 2027. The agency is not planning to hold an advisory committee meeting to discuss the application, the company said.
The acceptance of the NDA validates the clinical development of ulixacaltamide and is a significant de-risking event for Praxis Precision Medicines. It moves the company one step closer to accessing the large potential market for essential tremor treatments.
For investors, the definitive review timeline provides a key catalyst date. The company's ability to move ulixacaltamide through the regulatory process will be a central focus ahead of the 2027 PDUFA date.
This article is for informational purposes only and does not constitute investment advice.
Features
Resources
© 2026 Finture Development Limited. All rights reserved